CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML

References (7)

1. Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019;8:1279-1288
2. Allahbakhshian M, Shahabi Satlsar E, Mohseni A, Mosleh M, Mehrpouri M, Agaeipour M, Mohammadi MH, Gholampour R, Jadali F. Use of four-color flow cytometric assay for discrimination of hematogone from lymphoblast: critical issue for MRD assessment in B-ALL patients. Iran J Ped Hematol Oncol 2020;10:17-27
3. Yamazaki H, Xu CW, Naito M, Nishida H, Okamoto T, Ghani FI, Iwata S, Inukai T, Sugita K, Morimoto C. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. Biochem Biophys Res Commun 2011;409:14-21
4. Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med 2014;139:1308-1313
5. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003;17:707-715
6. Mosleh M, Mehrpouri M, Ghaffari S, Saei Z, Agaeipoor M, Jadali F, Satlsar ES, Gholampour R. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLADR negative non-APL leukemia. Scand J Clin Lab Invest 2020;80:87-92
7. Akhtar K, Ahmad S, Shervani RK. Acute promyelocytic leukemia, hypogranular variant: a rare presentation. Clin Pract 2011;1:e11.